Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

High Exposure of Rabbit Anti-Thymocyte Globulin (ATG) Is Strongly Associated with Inferior DFS in Pediatric Patients with Malignancy Undergoing Alpha-Beta T-Cell Depleted Haploidentical HCT

Christopher C Dvorak, Lucia Holbrook-Brown, Janel R. Long-Boyle, Hisham Abdel-Azim, Anant Vatsayan, Julie-An Talano, Nancy Bunin, Eric Jon Anderson, Allyson Flower, Nahal Lalefar, Christine S Higham, Neena Kapoor, Maryanne Odinakachukwu, David A Jacobsohn, Michael A. Pulsipher

Blood (2023) 142 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2023-178925

Published: 2023

Journal Articles

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

Regina M. Myers, Sarah Mumanachit, Shannon L. Maude, Amanda M. Dinofia, Jason L. Freedman, Nancy Bunin, Lisa Wray, Allison Barz Leahy, Timothy S Olson, Stephan Grupp, Alix E. Seif, Caitlin W. Elgarten

Blood (2023) 142 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2023-188047

Published: 2023

Journal Articles

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Blood (2023) 142 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2023-188013

Published: 2023

Journal Articles

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Blood (2021) 138 (Supplement 1): 476.

https://doi.org/10.1182/blood-2021-145620

Published: 2021

Journal Articles

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Joseph H Oved, Caitlin W Elgarten, Yongping Wang, Stephan Kadauke, Dimitri S. Monos, David M. Barrett, Stephan A. Grupp, Nancy Bunin, Timothy S. Olson

Blood (2021) 138 (Supplement 1): 171.

https://doi.org/10.1182/blood-2021-154305

Published: 2021

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Monica S. Thakar, Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, David A. Jacobsohn, Alison W. Loren, Joanne Kurtzberg, Caridad A. Martinez, Shin Mineishi, Adam S. Nelson, Ann Woolfrey, Marcelo C. Pasquini, Mohamed L. Sorror

Blood (2019) 133 (7): 754–762.

https://doi.org/10.1182/blood-2018-09-876284

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder

Susan Prockop, MD, Ai Li, PhD, Robert A Baiocchi, MD PhD, Nancy Bunin, MD, Kris Michael Mahadeo, MD, Eneida R. Nemecek, MD, Sarah Nikiforow, MD PhD, Ran Reshef, MD, Donald Edward Tsai, MD PhD, Willis H. Navarro, MD, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 4520.

https://doi.org/10.1182/blood.V130.Suppl_1.4520.4520

Published: 2017

Journal Articles

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Michael A. Pulsipher, Chris Carlson, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, Ilan Kirsch, Julie M. Gastier-Foster, Michael Borowitz, Cindy Desmarais, David Williamson, Michael Kalos, Stephan A. Grupp

Blood (2015) 125 (22): 3501–3508.

https://doi.org/10.1182/blood-2014-12-615757

Published: 2015

Includes: Supplemental data

Journal Articles

Non-Myeloablative Conditioning Targeting Host Immunosuppression Is Successful in Matched Sibling Donor Stem Cell Transplantation for Hemoglobinopathies in Children

Blood (2014) 124 (21): 3873.

https://doi.org/10.1182/blood.V124.21.3873.3873

Published: 2014

Journal Articles

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation

Richard Aplenc, Mei-Jie Zhang, Lillian Sung, Xiaochun Zhu, Vincent T. Ho, Kenneth Cooke, Christopher Dvorak, Gregory Hale, Luis M. Isola, Hillard M. Lazarus, Philip L. McCarthy, Richard Olsson, Michael Pulsipher, Marcelo C. Pasquini, Nancy Bunin

Blood (2014) 123 (22): 3504–3511.

https://doi.org/10.1182/blood-2013-03-490334

Published: 2014

Includes: Supplemental data

Journal Articles

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Michael A. Pulsipher, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, William L. Carroll, Elizabeth Raetz, Sharon Gardner, Julie M. Gastier-Foster, Denise Howrie, Rakesh K. Goyal, James G. Douglas, Michael Borowitz, Yvonne Barnes, David T. Teachey, Candace Taylor, Stephan A. Grupp

Blood (2014) 123 (13): 2017–2025.

https://doi.org/10.1182/blood-2013-10-534297

Published: 2014

Journal Articles

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study

Michael A. Pulsipher, MD, Christopher S Carlson, PhD, Krailo Mark, PhD, Donna A. Wall, MD, Kirk R. Schultz, MD, Nancy Bunin, MD, Michael Kalos, PhD, Desmarias Cindy, PhD, David Williamson, PhD, Gastier-Foster Julie, MD, PhD, Michael J. Borowitz, MD, PhD, Stephan A. Grupp, MD, PhD

Blood (2013) 122 (21): 919.

https://doi.org/10.1182/blood.V122.21.919.919

Published: 2013

Journal Articles

The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse

Michael A. Pulsipher, MD, Bryan Langholz, PhD, Donna A. Wall, MD, Kirk R. Schultz, MD, Nancy Bunin, MD, Julie M. Gastier-Foster, PhD, Michael J. Borowitz, MD, PhD, Rakesh Goyal, MD, MRCP, Sharon Gardner, MD, William L. Carroll, MD, Elizabeth Raetz, MD, Stephan A. Grupp, MD, PhD

Blood (2012) 120 (21): 470.

https://doi.org/10.1182/blood.V120.21.470.470

Published: 2012

Journal Articles

A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431

Michael A. Pulsipher, MD, Bryan Langholz, PhD, Donna A. Wall, MD, Kirk R. Schultz, MD, Nancy Bunin, MD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Sharon Gardner, MD, Julie M. Gastier-Foster, PhD, Denise Howrie, PharmD, Rakesh Goyal, MD, MRCP, Douglas James, MD, MRCP, Michael J. Borowitz, MD, PhD, Yvonne Jean Barnes, RN MSN CPNP, Shivanand R. Patil, PhD, David T Teachey, MD, Candace Taylor, CCRP, Stephan A Grupp, MD, PhD

Blood (2011) 118 (21): 837.

https://doi.org/10.1182/blood.V118.21.837.837

Published: 2011

Journal Articles

Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL.

Michael Pulsipher, Donna Wall, Stephan Grupp, Rakesh Goyal, Nancy Bunin

Blood (2006) 108 (11): 2876.

https://doi.org/10.1182/blood.V108.11.2876.2876

Published: 2006

Journal Articles

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation

David L. Porter, Bruce L. Levine, Nancy Bunin, Edward A. Stadtmauer, Selina M. Luger, Steven Goldstein, Alison Loren, Julie Phillips, Sunita Nasta, Alexander Perl, Steven Schuster, Donald Tsai, Ambika Sohal, Elizabeth Veloso, Stephen Emerson, Carl H. June

Blood (2006) 107 (4): 1325–1331.

https://doi.org/10.1182/blood-2005-08-3373

Published: 2006

Journal Articles

Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias.

Nancy Bunin, M.D., Stephan Grupp, M.D. Ph.D., Giuliana Pierson, Ph.D., Robert Iannone, M.D., Dmitri Monos, Ph.D., Richard Aplenc, M.D.

Blood (2004) 104 (11): 2159.

https://doi.org/10.1182/blood.V104.11.2159.2159

Published: 2004

NARROW

High Exposure of Rabbit Anti-Thymocyte Globulin (ATG) Is Strongly Associated with Inferior DFS in Pediatric Patients with Malignancy Undergoing Alpha-Beta T-Cell Depleted Haploidentical HCT

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Non-Myeloablative Conditioning Targeting Host Immunosuppression Is Successful in Matched Sibling Donor Stem Cell Transplantation for Hemoglobinopathies in Children

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study

The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse

A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431

Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation

Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only